Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival

识别儿童白血病存活小鼠模型中认知缺陷的致病因素

基本信息

  • 批准号:
    10442744
  • 负责人:
  • 金额:
    $ 52.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-07 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract Survival rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer, are now close to 90%, but survivors of childhood cancer are at an increased risk for long term cognitive deficits, particularly affecting executive function (e.g., attention, planning, inhibitory control, cognitive flexibility). The chemotherapeutic agent methotrexate (MTX) is used to treat most ALL patients, and is closely associated with executive function deficits. Thus a pressing need exists to define the mechanisms that link MTX exposure to cognitive dysfunction, to guide development of intervention strategies to protect the developing brain, reduce symptoms and optimize quality of life in ALL survivors, during childhood, adolescence, young and full adulthood. To that end, we have developed a translationally relevant mouse model of leukemia survival that combines cancer exposure (mouse leukemic cell line (L1210 cells) with contemporary chemotherapeutic drugs (vincristine and MTX, with leucovorin rescue) administered during early life. PFC development extends through adolescence, which renders this area of the brain particularly vulnerable to early life chemotherapy. Providing a solid premise for the proposed experiments, our mouse model recapitulates executive function deficits observed in ALL patients. Additionally, in response to early life cancer + chemotherapy, we have found an increase in the proinflammatory molecules IL-1 and CCL2, as well as a decrease in white matter associated genes within the PFC. In Aim 1, single cell RNA sequencing will be used to define the effects of cancer and/or chemotherapy on the transcriptional profile of the PFC. MTX disrupts folate metabolism to inhibit cell growth, but this disruption also leads to increased levels of the proinflammatory metabolite, homocysteine (HCY), in both plasma and cerebrospinal fluid. Increased HCY can drive inflammation, oxidative stress and is associated with both white and gray matter damage, as well as cognitive impairment. Further executive function deficits have also been linked to altered synaptic function, and microglia, a brain resident immune cell, can contribute to synapse elimination via the CD11b(CR3)-C3 phagocytic pathway. Therefore, we hypothesize that MTX-driven increased HCY levels will lead to neuroinflammation and oxidative stress, leading to gray and white matter damage, and altered synaptic pruning in the prefrontal cortex, which underlie deficits in executive function. To test this hypothesis, HCY-lowering strategies (folate and B vitamin supplementation, or the antioxidant, N-acetylcysteine amide) will be evaluated in Aim 2. Aim 3 will test the necessity of IL-1 activity while Aim 4 will test the necessity of microglia in mediating the chemotherapy-associated cognitive deficits, as well as neuroinflammation and oxidative stress, leading to gray and white matter damage, and altered synaptic pruning in the prefrontal cortex
摘要 急性淋巴细胞性白血病(ALL)是最常见的儿童癌症,其存活率现在是 接近90%,但儿童癌症幸存者患长期认知缺陷的风险增加, 尤其影响执行功能(例如,注意力、计划、抑制控制、认知灵活性)。 化疗药物甲氨蝶呤(MTX)用于治疗大多数ALL患者, 与执行功能缺陷有关。因此,迫切需要确定将 MTX暴露于认知功能障碍,以指导制定干预策略,以保护 发展大脑,减轻症状,优化所有幸存者的生活质量,在童年时期, 青春期、青春期和完全成年期。 为此,我们开发了一种与白血病存活的翻译相关的小鼠模型 将癌症暴露(小鼠白血病细胞系L1210细胞)与当代化疗相结合 在生命早期使用药物(长春新碱和甲氨蝶呤,配合亚叶酸钙抢救)。功率因数校正发展 一直延伸到青春期,这使得大脑的这一区域特别容易受到早期生命的影响 化疗。为拟议的实验提供了坚实的前提,我们的小鼠模型概括了 所有患者均观察到执行功能障碍。此外,为了应对早期癌症+ 化疗后,我们发现促炎分子IL-1和CCL2增加,以及 前额叶内脑白质相关基因减少。在目标1中,单细胞RNA测序将是 用于定义癌症和/或化疗对PFC转录图谱的影响。 MTX扰乱叶酸代谢以抑制细胞生长,但这种破坏也会导致水平上升 促炎症代谢物同型半胱氨酸(HCY)在血浆和脑脊液中的含量。增加了 HCY可以促进炎症和氧化应激,并与白质和灰质损伤有关, 以及认知障碍。进一步的执行功能缺陷也与改变有关 突触功能和小胶质细胞,一种脑内常驻免疫细胞,可以通过 CD11b(CR3)-C3吞噬途径。因此,我们假设MTX驱动的HCY增加 水平会导致神经炎症和氧化应激,导致灰质和白质损伤,以及 前额叶皮质突触修剪改变,这是执行功能缺陷的基础。 为了验证这一假设,降低HCY的策略(叶酸和B维生素补充剂,或 抗氧化剂,N-乙酰半胱氨酸酰胺)将在目标2中进行评估。目标3将测试IL-1活性的必要性 而目标4将测试小胶质细胞在调节化疗相关认知过程中的必要性 缺陷,以及神经炎症和氧化应激,导致灰质和白质损伤,以及 前额叶皮质突触修剪的改变

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TERESA M REYES其他文献

TERESA M REYES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TERESA M REYES', 18)}}的其他基金

Research Innovation in NeuroScience Education for Underserved Populations (RISE UP)
服务不足人群神经科学教育的研究创新 (RISE UP)
  • 批准号:
    9919943
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival
识别儿童白血病存活小鼠模型中认知缺陷的致病因素
  • 批准号:
    10256061
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
Research Innovation in NeuroScience Education for Underserved Populations (RISE UP)
服务不足人群神经科学教育的研究创新 (RISE UP)
  • 批准号:
    10599189
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
Biomedical Postbaccalaureate Research Education Program at the University of Cincinnati College of Medicine (PREP@UC)
辛辛那提大学医学院生物医学学士后研究教育计划 (PREP@UC)
  • 批准号:
    10267207
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival
识别儿童白血病存活小鼠模型中认知缺陷的致病因素
  • 批准号:
    10649734
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
DAT18-09 Maternal opioid exposure and executive function evaluation in the mouse
DAT18-09 母体阿片类药物暴露和小鼠执行功能评估
  • 批准号:
    9980856
  • 财政年份:
    2019
  • 资助金额:
    $ 52.95万
  • 项目类别:
DAT18-09 Maternal opioid exposure and executive function evaluation in the mouse
DAT18-09 母体阿片类药物暴露和小鼠执行功能评估
  • 批准号:
    9814868
  • 财政年份:
    2019
  • 资助金额:
    $ 52.95万
  • 项目类别:
PNIRS 2017 Annual Meeting
PNIRS 2017 年会
  • 批准号:
    9339045
  • 财政年份:
    2017
  • 资助金额:
    $ 52.95万
  • 项目类别:
Opioids and impulsivity: Neuroanatomical examination in a novel animal model
阿片类药物和冲动:新型动物模型的神经解剖学检查
  • 批准号:
    9137707
  • 财政年份:
    2015
  • 资助金额:
    $ 52.95万
  • 项目类别:
Opioids and impulsivity: Neuroanatomical examination in a novel animal model
阿片类药物和冲动:新型动物模型的神经解剖学检查
  • 批准号:
    8838567
  • 财政年份:
    2015
  • 资助金额:
    $ 52.95万
  • 项目类别:

相似海外基金

Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
  • 批准号:
    20K08723
  • 财政年份:
    2020
  • 资助金额:
    $ 52.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
  • 批准号:
    9047400
  • 财政年份:
    2015
  • 资助金额:
    $ 52.95万
  • 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
  • 批准号:
    319114
  • 财政年份:
    2014
  • 资助金额:
    $ 52.95万
  • 项目类别:
    Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
  • 批准号:
    8595788
  • 财政年份:
    2013
  • 资助金额:
    $ 52.95万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8023518
  • 财政年份:
    2011
  • 资助金额:
    $ 52.95万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8404025
  • 财政年份:
    2011
  • 资助金额:
    $ 52.95万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8220724
  • 财政年份:
    2011
  • 资助金额:
    $ 52.95万
  • 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
  • 批准号:
    8599754
  • 财政年份:
    2011
  • 资助金额:
    $ 52.95万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8356701
  • 财政年份:
    2010
  • 资助金额:
    $ 52.95万
  • 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
  • 批准号:
    8166720
  • 财政年份:
    2009
  • 资助金额:
    $ 52.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了